Johnson & Johnson (JNJ) stock
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3086% above fair value
$278.70−3.85 (-1.36%)
Close on Nov 17, 2026Market cap $670.92BP/E 42.3Yield 1.84%
Johnson & Johnson r&d expenses
Research and development expenses are spending on new products and technology.
Johnson & Johnson's R&D Expenses for the twelve months ending Oct 1, 2023 was $14.78B, down 3.8% year over year. For fiscal 2025 it was $109.00M, down 94.1% from the year before. Over ten years it grew -35.7% a year on average. The highest annual figure on record is $12.16B in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $109.00M | -94.1% |
| FY2024 | Dec 29, 2024 | $1.84B | +281.2% |
| FY2023 | Dec 31, 2023 | $483.00M | – |
| FY2022 | Jan 1, 2023 | $0 | – |
| FY2021 | Jan 2, 2022 | $0 | -100.0% |
| FY2020 | Jan 3, 2021 | $12.16B | +7.1% |
| FY2019 | Dec 29, 2019 | $11.36B | +5.4% |
| FY2018 | Dec 30, 2018 | $10.78B | +1.7% |
| FY2017 | Dec 31, 2017 | $10.59B | +15.9% |
| FY2016 | Jan 1, 2017 | $9.14B | +1.1% |
| FY2015 | Jan 3, 2016 | $9.05B | +6.5% |
| FY2014 | Dec 28, 2014 | $8.49B | +3.8% |
| FY2013 | Dec 29, 2013 | $8.18B | +6.8% |
| FY2012 | Dec 30, 2012 | $7.67B | +1.6% |
| FY2011 | Jan 1, 2012 | $7.55B | +10.3% |
| FY2010 | Jan 2, 2011 | $6.84B | -2.0% |
| FY2009 | Jan 3, 2010 | $6.99B | -7.8% |
| FY2008 | Dec 28, 2008 | $7.58B | -1.3% |
| FY2007 | Dec 30, 2007 | $7.68B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $4.65B | +32.3% |
| Q2 FY2026 | Jun 28, 2026 | $3.65B | +13.3% |
| Q1 FY2026 | Mar 29, 2026 | $3.53B | -28.8% |
| Q3 FY2025 | Sep 28, 2025 | $3.67B | +6.7% |
| Q2 FY2025 | Jun 29, 2025 | $3.52B | -0.7% |
| Q1 FY2025 | Mar 30, 2025 | $3.23B | -6.4% |
| Q3 FY2024 | Sep 29, 2024 | $4.95B | +33.7% |
| Q2 FY2024 | Jun 30, 2024 | $3.44B | -0.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.54B | -15.2% |
| Q3 FY2023 | Oct 1, 2023 | $3.45B | -1.1% |
| Q2 FY2023 | Jul 2, 2023 | $3.70B | 0.0% |
| Q1 FY2023 | Apr 2, 2023 | $3.46B | -0.2% |
| Q4 FY2022 | Jan 1, 2023 | $4.18B | -11.5% |
| Q3 FY2022 | Oct 2, 2022 | $3.49B | +1.8% |
| Q2 FY2022 | Jul 3, 2022 | $3.70B | +9.1% |
| Q1 FY2022 | Apr 3, 2022 | $3.46B | +8.9% |
| Q4 FY2021 | Jan 2, 2022 | $4.72B | +17.1% |
| Q3 FY2021 | Oct 3, 2021 | $3.42B | +20.5% |
| Q2 FY2021 | Jul 4, 2021 | $3.39B | +25.4% |
| Q1 FY2021 | Apr 4, 2021 | $3.18B | +23.2% |
| Q4 FY2020 | Jan 3, 2021 | $4.03B | +24.8% |
| Q3 FY2020 | Sep 27, 2020 | $2.84B | +9.3% |
| Q2 FY2020 | Jun 28, 2020 | $2.71B | +1.5% |
| Q1 FY2020 | Mar 29, 2020 | $2.58B | -9.7% |
| Q4 FY2019 | Dec 29, 2019 | $3.23B | +0.2% |
| Q3 FY2019 | Sep 29, 2019 | $2.60B | +3.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.67B | +1.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.86B | +18.9% |
| Q4 FY2018 | Dec 30, 2018 | $3.22B | -11.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.51B | -3.0% |
| Q2 FY2018 | Jul 1, 2018 | $2.64B | +14.9% |
| Q1 FY2018 | Apr 1, 2018 | $2.40B | +16.1% |
| Q4 FY2017 | Dec 31, 2017 | $3.64B | +35.5% |
| Q3 FY2017 | Oct 1, 2017 | $2.59B | – |
| Q2 FY2017 | Jul 2, 2017 | $2.30B | – |
| Q1 FY2017 | Apr 2, 2017 | $2.07B | – |
| Q4 FY2016 | Jan 1, 2017 | $2.69B | – |
See a number that looks wrong?